{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etanercept+%28Enbrel%29&page=2", "query": { "intervention": "Etanercept (Enbrel)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 167, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etanercept+%28Enbrel%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etanercept+%28Enbrel%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T07:44:03.224Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02092467", "title": "Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "tofacitinib", "type": "DRUG" }, { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 4372, "start_date": "2014-03-14", "completion_date": "2020-07-22", "has_results": true, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092467" }, { "nct_id": "NCT03792841", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "acapatamab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Cytochrome P450 (CYP) Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 212, "start_date": "2019-02-05", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 13, "location_summary": "Campbell, California • Duarte, California • Long Beach, California + 9 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03792841" }, { "nct_id": "NCT03915964", "title": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2659, "start_date": "2019-04-25", "completion_date": "2025-05-28", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 81, "location_summary": "Flagstaff, Arizona • Gilbert, Arizona • Glendale, Arizona + 69 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915964" }, { "nct_id": "NCT02464878", "title": "Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant", "Type 1 Diabetes" ], "interventions": [ { "name": "Alpha 1-Antitrypsin", "type": "DRUG" }, { "name": "Islet Transplantation", "type": "PROCEDURE" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2017-01", "completion_date": "2022-12", "has_results": true, "last_update_posted_date": "2023-12-22", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464878" }, { "nct_id": "NCT01764997", "title": "An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Placebo (for etanercept)", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2013-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2017-07-27", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Victorville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764997" }, { "nct_id": "NCT02115750", "title": "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "CHS-0214", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 647, "start_date": "2014-05", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2019-06-26", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115750" }, { "nct_id": "NCT00566813", "title": "Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Islet Cell Transplant", "type": "DRUG" }, { "name": "Islet Cell Transplant plus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2004-11", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566813" }, { "nct_id": "NCT00127387", "title": "Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lung Cancer", "Prostate Cancer", "Neoplasm Metastasis", "Bone Cancer" ], "interventions": [ { "name": "Enbrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2001-05", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2012-06-26", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127387" }, { "nct_id": "NCT00048373", "title": "Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Histiocytosis, Langerhans-Cell" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Day to 65 Years" }, "enrollment_count": 20, "start_date": "2001-10", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048373" }, { "nct_id": "NCT00796705", "title": "Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-11", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-06T07:44:03.224Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796705" } ] }